Amgen, Cytokinetics Announce Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil Did Not Meet Primary Endpoint

By: Benzinga
Amgen (NASDAQ: AMGN ) and Cytokinetics Incorporated (NASDAQ: CYTK ) today announced the first presentation of data from the ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) study at the ESC Congress 2013, organized by the European Society of Cardiology, in Amsterdam. ATOMIC-AHF
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.